-
Something wrong with this record ?
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group
M. Santoni, S. Buti, ZW. Myint, M. Maruzzo, R. Iacovelli, M. Pichler, J. Kopecky, J. Kucharz, M. Rizzo, L. Galli, T. Büttner, U. De Giorgi, R. Kanesvaran, O. Fiala, E. Grande, PA. Zucali, RM. Kopp, G. Fornarini, MT. Bourlon, S. Scagliarini, J....
Language English Country Netherlands
Document type Journal Article
- MeSH
- Tyrosine Kinase Inhibitors MeSH
- Carcinoma, Renal Cell * drug therapy pathology MeSH
- Humans MeSH
- Kidney Neoplasms * drug therapy MeSH
- Retrospective Studies MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Renal c carcinoma (RCC) is one of the most common urinary cancers worldwide, with a predicted increase in incidence in the coming years. Immunotherapy, as a single agent, in doublets, or in combination with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKIs), has rapidly become a cornerstone of the RCC therapeutic scenario, but no head-to-head comparisons have been made. In this setting, real-world evidence emerges as a cornerstone to guide clinical decisions. OBJECTIVE: The objective of this retrospective study was to assess the outcome of patients treated with first-line immune combinations or immune oncology (IO)-TKIs for advanced RCC. DESIGN, SETTING, AND PARTICIPANTS: Data from 930 patients, 654 intermediate risk and 276 poor risk, were collected retrospectively from 58 centers in 20 countries. Special data such as sarcomatoid differentiation, body mass index, prior nephrectomy, and metastatic localization, in addition to biochemical data such as hemoglobin, platelets, calcium, lactate dehydrogenase, neutrophils, and radiological response by investigator's criteria, were collected. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. The median follow-up was calculated by the inverse Kaplan-Meier method. RESULTS AND LIMITATIONS: The median follow-up time was 18.7 mo. In the 654 intermediate-risk patients, the median OS and PFS were significantly longer in patients with the intermediate than in those with the poor International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria (38.9 vs 17.3 mo, 95% confidence interval [CI] p < 0.001, and 17.3 vs 11.6 mo, 95% CI p < 0.001, respectively). In the intermediate-risk subgroup, the OS was 55.7 mo (95% CI 31.4-55.7) and 40.2 mo (95% CI 29.6-51.6) in patients treated with IO + TKI and IO + IO combinations, respectively (p = 0.047). PFS was 30.7 mo (95% CI 16.5-55.7) and 13.2 mo (95% CI 29.6-51.6) in intermediate-risk patients treated with IO + TKI and IO + IO combinations, respectively (p < 0.001). In the poor-risk subgroup, the median OS and PFS did not show a statistically significant difference between IO + IO and IO + TKI. Our study presents several limitations, mainly due to its retrospective nature. CONCLUSIONS: Our results showed differences between the IO + TKI and IO + IO combinations in intermediate-risk patients. A clear association with longer PFS and OS in favor of patients who received the IO + TKI combinations compared with the IO-IO combination was observed. Instead, in the poor-risk group, we observed no significant difference in PFS or OS between patients who received different combinations. PATIENT SUMMARY: Renal cancer is one of the most frequent genitourinary tumors. Treatment is currently based on immunotherapy combinations or immunotherapy with tyrosine kinase inhibitors, but there are no comparisons between these.In this study, we have analyzed the clinical course of 930 patients from 58 centers in 20 countries around the world. We aimed to analyze the differences between the two main treatment strategies, combination of two immunotherapies versus immunotherapy + antiangiogenic therapy, and found in real-life data that intermediate-risk patients (approximately 60% of patients with metastatic renal cancer) seem to benefit more from the combination of immunotherapy + antiangiogenic therapy than from double immunotherapy. No such differences were found in poor-risk patients. This may have important implications in daily practice decision-making for these patients.
Azienda Ospedaliero Universitario Mater Domini Policlinico of Catanzaro Catanzaro Italy
Clinical Oncology Sociedad de oncología y hematología del Cesar Valledupar Colombia
Department of Biomedical Sciences Humanitas University Pieve Emanuele Milan Italy
Department of Internal Medicine and Medical Specialties University of Genoa Genoa Italy
Department of Internal Medicine Hematology Oncology Ochsner Medical Center New Orleans LA USA
Department of Medical Oncology Army Hospital Research and Referral New Delhi India
Department of Medical Oncology Centre Hospitalier de Jolimont Haine Saint Paul Belgium
Department of Medical Oncology Hospital Ramón y Cajal Madrid Spain
Department of Medical Oncology Maggiore della Carità University Hospital Novara Italy
Department of Medical Oncology MD Anderson Cancer Center Madrid Madrid Spain
Department of Oncology IRCCS Humanitas Research Hospital Rozzano Milan Italy
Department of Oncology San Camillo Forlanini Hospital Rome Italy
Department of Oncology Tays Cancer Center Tampere University Hospital Tampere Finland
Department of Urology Medical University of Innsbruck Innsbruck Austria
Department of Urology University Hospital Bonn Bonn Germany
Dipartimento di Oncologia Medica Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
Division of Medical Oncology A O U Consorziale Policlinico di Bari Bari Italy
Division of Medical Oncology National Cancer Centre Singapore Singapore
Division of Oncology Department of Internal Medicine Medical University of Graz Graz Austria
Division of Oncology Institute for Cancer Research and Treatment Alba Brà Italy
Hospital Israelita Albert Einstein São Paulo SP Brazil
Interdisciplinary Department of Medicine University of Bari Aldo Moro Bari Italy
IRCCS Ospedale Policlinico San Martino Genoa Italy
Klinik für Urologie Lübeck Germany
Latin American Cooperative Oncology Group LACOG Porto Alegre Brazil
Markey Cancer Center University of Kentucky Lexington KY USA
Medical and Translational Oncology Azienda Ospedaliera Santa Maria Terni Italy
Medical Oncology 1 IRCCS Regina Elena National Cancer Institute Rome Italy
Medical Oncology Department La Paz University Hospital Madrid Spain
Medical Oncology IRCCS Azienda Ospedaliero Universitaria di Bologna Bologna Italia
Medical Oncology Ospedale San Paolo Savona Italy
Medical Oncology Tawam Hospital Al Ain United Arab Emirates
Medical Oncology Unit Gemelli Molise Hospital Università Cattolica del Sacro Cuore Campobasso Italy
Medical Oncology Unit Santa Chiara Hospital Trento Italy
Oncologia Medica Fondazione Policlinico Universitario Agostino Gemelli IRCCS Roma Italy
Oncologia Medica Ospedale Maggiore di Cremona Cremona Italy
Oncology 3 Unit Department of Oncology Istituto Oncologico Veneto IOV IRCCS Padova Italy
Oncology and Hematology Department Hospital Santa Lucia Brasília Brazil
Oncology Candiolo Cancer Institute IRCCS FPO Torino Italy
Oncology Unit 2 University Hospital of Pisa Pisa Italy
Oncology Unit A R N A S Civico Palermo Italy
Oncology Unit Macerata Hospital Macerata Italy
Unità di Oncologia Medica Azienda Ospedaliero Universitaria di Cagliari Cagliari Italy
UOC di Oncologia Azienda Ospedaliera di Rilievo Nazionale Cardarelli di Napoli Naples Italy
UOC Oncologia Azienda Ospedaliera Ospedali Riuniti Marche Nord Italy
UOC Oncologia Medica Ospedale A Murri Fermo Italy
Urologic Oncology Champalimaud Clinical Center Lisbon Portugal
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007457
- 003
- CZ-PrNML
- 005
- 20240423155958.0
- 007
- ta
- 008
- 240412s2024 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.euo.2023.07.003 $2 doi
- 035 __
- $a (PubMed)37481365
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Santoni, Matteo $u Oncology Unit, Macerata Hospital, Macerata, Italy
- 245 10
- $a Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group / $c M. Santoni, S. Buti, ZW. Myint, M. Maruzzo, R. Iacovelli, M. Pichler, J. Kopecky, J. Kucharz, M. Rizzo, L. Galli, T. Büttner, U. De Giorgi, R. Kanesvaran, O. Fiala, E. Grande, PA. Zucali, RM. Kopp, G. Fornarini, MT. Bourlon, S. Scagliarini, J. Molina-Cerrillo, G. Aurilio, MR. Matrana, R. Pichler, C. Cattrini, T. Büchler, F. Massari, E. Seront, F. Calabrò, A. Pinto, R. Berardi, A. Zgura, G. Mammone, J. Ansari, F. Atzori, R. Chiari, A. Bamias, O. Caffo, G. Procopio, K. Sunela, M. Bassanelli, C. Ortega, F. Grillone, J. Landmesser, M. Milella, C. Messina, Z. Küronya, A. Mosca, D. Bhuva, D. Santini, N. Vau, F. Morelli, L. Incorvaia, SE. Rebuzzi, G. Roviello, A. Soares, R. Bisonni, D. Bimbatti, IO. Zabalza, A. Rizzo, V. Mollica, G. Sorgentoni, FSM. Monteiro, N. Battelli, S. Bracarda, C. Porta
- 520 9_
- $a BACKGROUND: Renal c carcinoma (RCC) is one of the most common urinary cancers worldwide, with a predicted increase in incidence in the coming years. Immunotherapy, as a single agent, in doublets, or in combination with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKIs), has rapidly become a cornerstone of the RCC therapeutic scenario, but no head-to-head comparisons have been made. In this setting, real-world evidence emerges as a cornerstone to guide clinical decisions. OBJECTIVE: The objective of this retrospective study was to assess the outcome of patients treated with first-line immune combinations or immune oncology (IO)-TKIs for advanced RCC. DESIGN, SETTING, AND PARTICIPANTS: Data from 930 patients, 654 intermediate risk and 276 poor risk, were collected retrospectively from 58 centers in 20 countries. Special data such as sarcomatoid differentiation, body mass index, prior nephrectomy, and metastatic localization, in addition to biochemical data such as hemoglobin, platelets, calcium, lactate dehydrogenase, neutrophils, and radiological response by investigator's criteria, were collected. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. The median follow-up was calculated by the inverse Kaplan-Meier method. RESULTS AND LIMITATIONS: The median follow-up time was 18.7 mo. In the 654 intermediate-risk patients, the median OS and PFS were significantly longer in patients with the intermediate than in those with the poor International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria (38.9 vs 17.3 mo, 95% confidence interval [CI] p < 0.001, and 17.3 vs 11.6 mo, 95% CI p < 0.001, respectively). In the intermediate-risk subgroup, the OS was 55.7 mo (95% CI 31.4-55.7) and 40.2 mo (95% CI 29.6-51.6) in patients treated with IO + TKI and IO + IO combinations, respectively (p = 0.047). PFS was 30.7 mo (95% CI 16.5-55.7) and 13.2 mo (95% CI 29.6-51.6) in intermediate-risk patients treated with IO + TKI and IO + IO combinations, respectively (p < 0.001). In the poor-risk subgroup, the median OS and PFS did not show a statistically significant difference between IO + IO and IO + TKI. Our study presents several limitations, mainly due to its retrospective nature. CONCLUSIONS: Our results showed differences between the IO + TKI and IO + IO combinations in intermediate-risk patients. A clear association with longer PFS and OS in favor of patients who received the IO + TKI combinations compared with the IO-IO combination was observed. Instead, in the poor-risk group, we observed no significant difference in PFS or OS between patients who received different combinations. PATIENT SUMMARY: Renal cancer is one of the most frequent genitourinary tumors. Treatment is currently based on immunotherapy combinations or immunotherapy with tyrosine kinase inhibitors, but there are no comparisons between these.In this study, we have analyzed the clinical course of 930 patients from 58 centers in 20 countries around the world. We aimed to analyze the differences between the two main treatment strategies, combination of two immunotherapies versus immunotherapy + antiangiogenic therapy, and found in real-life data that intermediate-risk patients (approximately 60% of patients with metastatic renal cancer) seem to benefit more from the combination of immunotherapy + antiangiogenic therapy than from double immunotherapy. No such differences were found in poor-risk patients. This may have important implications in daily practice decision-making for these patients.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z renálních buněk $x farmakoterapie $x patologie $7 D002292
- 650 12
- $a nádory ledvin $x farmakoterapie $7 D007680
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a inhibitory tyrosinkinasy $7 D000092004
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Buti, Sebastiano $u Medical Oncology Unit, University Hospital of Parma - Department of Medicine and Surgery, University of Parma, Parma, Italy
- 700 1_
- $a Myint, Zin W $u Markey Cancer Center, University of Kentucky, Lexington, KY, USA
- 700 1_
- $a Maruzzo, Marco $u Oncology 3 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy
- 700 1_
- $a Iacovelli, Roberto $u Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
- 700 1_
- $a Pichler, Martin $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
- 700 1_
- $a Kopecky, Jindrich $u Department of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Kucharz, Jakub $u Department of Uro-oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Rizzo, Mimma $u Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy
- 700 1_
- $a Galli, Luca $u Oncology Unit 2, University Hospital of Pisa, Pisa, Italy
- 700 1_
- $a Büttner, Thomas $u Department of Urology, University Hospital Bonn (UKB), Bonn, Germany
- 700 1_
- $a De Giorgi, Ugo $u Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio deiTumori (IRST) "Dino Amadori", Meldola, Italy
- 700 1_
- $a Kanesvaran, Ravindran $u Division of Medical Oncology, National Cancer Centre Singapore, Singapore
- 700 1_
- $a Fiala, Ondřej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Grande, Enrique $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
- 700 1_
- $a Zucali, Paolo Andrea $u Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
- 700 1_
- $a Kopp, Ray Manneh $u Clinical Oncology, Sociedad de oncología y hematología del Cesar, Valledupar, Colombia
- 700 1_
- $a Fornarini, Giuseppe $u IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- 700 1_
- $a Bourlon, Maria T $u Hematology and Oncology Department, Instituto Nacional de Ciencias Médicasy Nutrición Salvador Zubirán, Mexico City, Mexico
- 700 1_
- $a Scagliarini, Sarah $u UOC di Oncologia, Azienda Ospedaliera di Rilievo Nazionale Cardarelli di Napoli, Naples, Italy
- 700 1_
- $a Molina-Cerrillo, Javier $u Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain. Electronic address: javier.molinace@gmail.com
- 700 1_
- $a Aurilio, Gaetano $u Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology, IRCCS, Milan, Italy
- 700 1_
- $a Matrana, Marc R $u Department of Internal Medicine, Hematology/Oncology, Ochsner Medical Center, New Orleans, LA, USA
- 700 1_
- $a Pichler, Renate $u Department of Urology, Medical University of Innsbruck, Innsbruck, Austria
- 700 1_
- $a Cattrini, Carlo $u Department of Medical Oncology, "Maggiore della Carità" University Hospital, Novara, Italy
- 700 1_
- $a Büchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
- 700 1_
- $a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italia
- 700 1_
- $a Seront, Emmanuel $u Department of Medical Oncology, Centre Hospitalier de Jolimont, Haine Saint Paul, Belgium
- 700 1_
- $a Calabrò, Fabio $u Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy
- 700 1_
- $a Pinto, Alvaro $u Medical Oncology Department, La Paz University Hospital, Madrid, Spain
- 700 1_
- $a Berardi, Rossana $u Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riunitidelle Marche, Ancona, Italy
- 700 1_
- $a Zgura, Anca $u Department of Oncology-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Mammone, Giulia $u Department of Radiological, Oncological and Anatomo-Pathological Science, "Sapienza" University of Rome, Rome, Italy
- 700 1_
- $a Ansari, Jawaher $u Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates
- 700 1_
- $a Atzori, Francesco $u Unità di Oncologia Medica, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy
- 700 1_
- $a Chiari, Rita $u UOC Oncologia, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Italy
- 700 1_
- $a Bamias, Aristotelis $u 2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Caffo, Orazio $u Medical Oncology Unit, Santa Chiara Hospital, Trento, Italy
- 700 1_
- $a Procopio, Giuseppe $u Dipartimento di Oncologia Medica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Oncologia Medica, Ospedale Maggiore di Cremona, Cremona, Italy
- 700 1_
- $a Sunela, Kaisa $u Department of Oncology, Tays Cancer Center, Tampere University Hospital, Tampere, Finland
- 700 1_
- $a Bassanelli, Maria $u Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy
- 700 1_
- $a Ortega, Cinzia $u Division of Oncology, Institute for Cancer Research and Treatment, Alba-Brà, Italy
- 700 1_
- $a Grillone, Francesco $u Azienda Ospedaliero-Universitario "Mater Domini", Policlinico of Catanzaro, Catanzaro, Italy
- 700 1_
- $a Landmesser, Johannes $u Klinik für Urologie, Lübeck, Germany
- 700 1_
- $a Milella, Michele $u Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy
- 700 1_
- $a Messina, Carlo $u Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy
- 700 1_
- $a Küronya, Zsófia $u Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary
- 700 1_
- $a Mosca, Alessandra $u Oncology, Candiolo Cancer Institute, IRCCS-FPO, Torino, Italy
- 700 1_
- $a Bhuva, Dipen $u Department of Medical Oncology, Army Hospital Research and Referral, New Delhi, India
- 700 1_
- $a Santini, Daniele $u Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza, University of Rome, Rome, Italy
- 700 1_
- $a Vau, Nuno $u Urologic Oncology, Champalimaud Clinical Center, Lisbon, Portugal
- 700 1_
- $a Morelli, Franco $u Medical Oncology Unit, Gemelli Molise Hospital, Università Cattolica del Sacro Cuore, Campobasso, Italy
- 700 1_
- $a Incorvaia, Lorena $u Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
- 700 1_
- $a Rebuzzi, Sara Elena $u Medical Oncology, Ospedale San Paolo, Savona, Italy; Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genoa, Genoa, Italy
- 700 1_
- $a Roviello, Giandomenico $u Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy
- 700 1_
- $a Soares, Andrey $u Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
- 700 1_
- $a Bisonni, Renato $u UOC Oncologia Medica, Ospedale A. Murri, Fermo, Italy
- 700 1_
- $a Bimbatti, Davide $u Oncology 3 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy
- 700 1_
- $a Zabalza, Ignacio Ortego $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
- 700 1_
- $a Rizzo, Alessandro $u Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy
- 700 1_
- $a Mollica, Veronica $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italia
- 700 1_
- $a Sorgentoni, Giulia $u Oncology Unit, Macerata Hospital, Macerata, Italy
- 700 1_
- $a Monteiro, Fernando Sabino M $u Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil; Oncology and Hematology Department, Hospital Santa Lucia, Brasília, Brazil
- 700 1_
- $a Battelli, Nicola $u Oncology Unit, Macerata Hospital, Macerata, Italy
- 700 1_
- $a Bracarda, Sergio $u Medical and Translational Oncology, "Azienda Ospedaliera Santa Maria", Terni, Italy
- 700 1_
- $a Porta, Camillo $u Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy; Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy
- 773 0_
- $w MED00205913 $t European urology oncology $x 2588-9311 $g Roč. 7, č. 1 (2024), s. 102-111
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37481365 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155954 $b ABA008
- 999 __
- $a ok $b bmc $g 2081446 $s 1217224
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 7 $c 1 $d 102-111 $e 20230721 $i 2588-9311 $m European urology oncology $n Eur Urol Oncol $x MED00205913
- LZP __
- $a Pubmed-20240412
